Brain-based vision loss, known as cerebral/cortical visual impairment (CVI) is a leading cause of blindness and visual impairment in children in the United States and other industrialized countries. However, our understanding of CVI is limited. Physicians don’t even agree on how to characterize it. Researchers at CHLA intend to change that and help guide how this disorder is diagnosed as well.
A new study shows that photoreceptor cells in the retina exhibit planar polarity, i.e. their light-sensitive cilia orient themselves in a coordinated manner.
According to the Centers for Disease Prevention and Control: 45% of playground injuries are considered severe—fractures, dislocations, and concussions. So it’s important for parents and caregivers to be aware of the physical cues that accompany common pediatric injuries.
Emmecell, a clinical-stage biotechnology company revolutionizing cell-based therapies for serious eye diseases, today announced exciting topline results from its U.S. multi-center Phase 1 extension study evaluating EO2002, a non-surgical cell therapy for corneal edema. The randomized, double-masked trial demonstrated significant improvements in vision and corneal health, alongside a strong safety profile.
Tufts University researcher dedicated to finding treatments for cancer by researching tumors that develop in Meibomian glands, the specialized oil-secreting glands of the eyelid.
The Division of Ophthalmology at Ann & Robert H. Lurie Children’s Hospital of Chicago recently became an Ocular Gene Therapy Treatment Center for LUXTURNA® (voretigene neparvovec-rzl), the first gene therapy approved in the U.S. to treat children and adult patients with a form of vision loss that can result in blindness.
A new study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet age-related macular degeneration (or “wet” AMD) fail to have vision improvement with treatment, but also how an experimental drug could be used with existing wet AMD treatments to save vision.
During November’s Diabetic Eye Disease Awareness Month, the American Society of Retina Specialists encourages people with diabetes, their friends, and loved ones to learn more about diabetic retinopathy and diabetic macular edema and prioritize their eye health to protect and preserve vision.
Fads tend to change in the blink of an eye. This year, some people are being drawn to an eye-catching social media trend of using eye drops that promise to lighten or darken your eye color. The reality is that over-the-counter eye drops cannot change your eye color.
Rensselaer Polytechnic Institute’s Christopher Cioffi, Ph.D., Thomas and Constance D'Ambra Professor in Organic Chemistry, has been collaborating with Konstantin Petrukhin, Ph.D., Professor of Ophthalmic Science at Columbia University, to develop compounds to treat dry age-related macular degeneration (AMD) and Stargardt disease — both blindness-causing diseases. The team’s work has led to the discovery of an advanced preclinical candidate. Now, Cioffi and Petrukhin have received a $6.4 million grant over five years from the National Institutes of Health’s National Eye Institute to conduct drug development work and investigational new drug (IND)-enabling toxicology studies.
Clinicians, researchers and the public are invited to learn about stem cell and gene therapies being developed throughout California at the 7th Annual Alpha Clinics Network Symposium, hosted by Cedars-Sinai on Oct. 25.
Through an initiative led by UdeM, a first cohort of students is graduating from the State University of Haiti’s School of Optometry. It's a story of perseverance in the face of adversity.
Study shows investigational treatment reduced vision loss and protected key structures in the eye essential for vision.
New research suggests that a new kind of gene therapy can improve vision in people who have lost nearly all sight to retinitis pigmentosa.
New study shows customized eyeglasses successfully addressed children’s complex eye needs.
Six-year study results show laser treatment can preserve vision better than daily eye drops in glaucoma patients.
Research shows people who develop allergies as children with it persisting into adulthood tend to experience more eye complications.
Year-long use of a typical antiviral treatment for shingles was particularly impactful in reducing complications when the condition eventually affected the eye
Showing results
1–1 of 1
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
